Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
11 March 2021 - 11:05PM
via InvestorWire – Annovis Bio, Inc., ANVS, today
announced that Maria Maccecchini, PhD, Founder, President and CEO,
will be attending the Q1 Virtual Investor Summit.
Event |
Q1 Investor Summit |
Date |
March 23-25th, 2021 |
Presentation |
March 24th @ 11:30AM ET |
Location |
https://zoom.us/webinar/register/WN_LKCiDrrKROa4nLfrPKSiAA |
About The Investor SummitThe Investor Summit
(formerly MicroCap Conference) is an exclusive, independent
conference dedicated to connecting smallcap and microcap companies
with qualified investors. The Q1 Investor Summit will take place
virtually, featuring 100 companies and over 300 institutional and
retail investors.
To request complimentary investor registration: please visit our
website at www.investorsummitgroup.com
Contact: Brittney Blocker
at brittney@investorsummitgroup.com
ABOUT Annovis Bio, IncAnnovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer's disease (AD),
Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have two ongoing Phase 2a
studies: one in AD patients and one in both AD and PD patients. For
more information on Annovis, please visit the company's website:
www.annovisbio.com.
Wire Service ContactInvestorWire (IW) Los
Angeles, Californiawww.InvestorWire.com212.418.1217
OfficeEditor@InvestorWire.com
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2024 to May 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From May 2023 to May 2024